Kura Oncology Stock News

Barclays PLC lifted its stake in shares of Kura Oncology Inc (NASDAQ:KURA) by 106.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The

Kura Oncology Inc (NASDAQ:KURA) has earned a consensus rating of “Buy” from the twelve brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stoc

KBC Group NV raised its stake in shares of Kura Oncology Inc (NASDAQ:KURA) by 104.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 4,850 shares of the com

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics...

Capital Impact Advisors LLC boosted its holdings in Kura Oncology Inc (NASDAQ:KURA) by 8.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange

Driehaus Capital Management LLC lowered its position in shares of Kura Oncology Inc (NASDAQ:KURA) by 91.4% during the 4th quarter, according to the company in its most recent disclosure with the Secur

Q4 2019 Kura Oncology Inc Earnings Call

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis...

Rhumbline Advisers boosted its position in shares of Kura Oncology Inc (NASDAQ:KURA) by 4.3% in the fourth quarter, Holdings Channel reports. The fund owned 42,200 shares of the company’s stock afte

The FDA has designated Kura Oncology's (NASDAQ:KURA) lead drug tipifarnib for Fast Track review for the treatment of adults with relapsed or refractory angioimmunoblastic T-cell lymphoma, follicular T

Kura Oncology Inc:

Kura Oncology receives Fast Track designation for tipifarnib in T-cell lymphomas KURA

Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Admini

Kura Oncology (NASDAQ:KURA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com report